| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Adrenaline sulfate targets α-adrenergic and β-adrenergic receptors as a direct agonist. Activation of α-adrenergic receptors leads to vasoconstriction, increased peripheral resistance, and elevated blood pressure. Activation of β-adrenergic receptors leads to positive chronotropic and inotropic effects on the heart, bronchodilation, and metabolic effects such as glycogenolysis. Adrenaline sulfate is a full agonist at all adrenergic receptor subtypes.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Adrenaline sulfate is a potent agonist at α- and β-adrenergic receptors, activating downstream signaling pathways such as cAMP production and intracellular calcium mobilization. The compound induces vasoconstriction in isolated blood vessels, positive inotropic effects in cardiac tissue, and relaxation of bronchial smooth muscle. Its efficacy at all adrenergic receptor subtypes is well-characterized.
|
| ln Vivo |
Rats administered intraperitoneally with L-adrenaline sulfate (0.75, 1.5, or 3 mg/kg) experience oxidative and nitrative stress, which worsens lipid and protein damage as well as cardiomyopathy and cytogenetic damage [2]. In mature pigs, L-adrenaline sulfate (0.02, 0.03 mg/kg) dramatically lowers organ and brain perfusion while slightly raising ABP and CePP [3]. In young adult rats, subcutaneous injection of L-epinephrine sulfate (0.1 mg/kg) improves memory partly via raising blood glucose levels necessary for memory regulation [6].
In vivo studies of Adrenaline sulfate are extensive, as the compound is a clinically used drug. It is administered intravenously, intramuscularly, subcutaneously, or orally for the treatment of anaphylaxis, cardiac arrest, and other emergency conditions. The compound rapidly raises blood pressure, increases cardiac output, and reverses bronchospasm. Its effects are dose-dependent and short-lived due to rapid metabolism. |
| Cell Assay |
Cellular assays for Adrenaline sulfate are conducted using cell lines expressing adrenergic receptors. Cells are treated with the compound, and downstream signaling is measured, including cAMP accumulation (for β-receptors) or calcium flux (for α-receptors). Functional assays in isolated tissues, such as aortic ring vasoconstriction or tracheal ring relaxation, are also performed to assess the compound's pharmacological activity.
|
| Animal Protocol |
Animal/Disease Models: 220-280 g, 18 weeks Wistar rats [2]
Doses: 0.75, 1.5, 3 mg/kg Route of Administration: IP Experimental Results: Induced CAT activity, MDA levels, PCC, NO2− and 3-NT were significant Elevated SOD activity Dramatically diminished, and the total activities of LDH, LDH1 and LDH2 isoenzymes increased. Animal/Disease Models: 24-25 month old male Fischer-344 rats [6] Doses: 0.1 mg/kg Route of Administration: subcutaneous injection Experimental Results: Enhanced memory in young adult rats by increasing blood sugar levels required to regulate memory. In vivo animal experiments with Adrenaline sulfate are conducted in various species to evaluate cardiovascular, respiratory, and metabolic effects. Blood pressure, heart rate, and cardiac output are monitored via telemetry or invasive catheters. Bronchospasm models are used to assess bronchodilatory efficacy. The compound's effects on glucose metabolism, including glycogenolysis and hyperglycemia, are also studied. |
| References |
| Molecular Formula |
C9H13NO3.H2O4S
|
|---|---|
| Molecular Weight |
281.2829
|
| Exact Mass |
210.125
|
| CAS # |
52455-32-0
|
| Related CAS # |
L-Epinephrine;51-43-4;L-Epinephrine-d3;1217733-17-9
|
| PubChem CID |
122037
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
301.3±42.0 °C at 760 mmHg
|
| Flash Point |
129.0±27.9 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.471
|
| LogP |
2.29
|
| tPSA |
156
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
235
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CNCC(C1=CC(=C(C=C1)O)O)O.OS(=O)(=O)O
|
| InChi Key |
NDOXJVMFOWUYBP-FVGYRXGTSA-N
|
| InChi Code |
InChI=1S/C9H13NO3.H2O4S/c1-10-5-9(13)6-2-3-7(11)8(12)4-6;1-5(2,3)4/h2-4,9-13H,5H2,1H3;(H2,1,2,3,4)/t9-;/m0./s1
|
| Chemical Name |
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5552 mL | 17.7759 mL | 35.5518 mL | |
| 5 mM | 0.7110 mL | 3.5552 mL | 7.1104 mL | |
| 10 mM | 0.3555 mL | 1.7776 mL | 3.5552 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.